ZI KL1 1
Alternative Names: ZI-KL1-1Latest Information Update: 03 Mar 2023
At a glance
- Originator Zelluna Immunotherapy
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Cervical cancer; Gastric cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 30 Jan 2023 Preclinical trials in Breast cancer in Norway (Parenteral) (Zelluna Immunotherapy pipeline, January 2023)
- 30 Jan 2023 Preclinical trials in Cervical cancer in Norway (Parenteral) (Zelluna Immunotherapy pipeline, January 2023)
- 30 Jan 2023 Preclinical trials in Gastric cancer in Norway (Parenteral) (Zelluna Immunotherapy pipeline, January 2023)